ANNAPOLIS, Maryland, 21 août 2024 /PRNewswire/ — Alphyn, une société de dermatologie au stade clinique qui développe des produits thérapeutiques multicibles de premier plan, les Multi-Target Therapeutics®, annonce ce jour avoir reçu un avis d’acceptation de revendications de l’Office…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.